Answer
Selpercatinib targets cancers driven by particular RET fusions or mutations. Testing confirms whether the tumour has an alteration covered by the licensed indications.
Sources for this answer
- Retsevmo 40mg and 80mg film-coated tablets — Current selected SmPCemc · Summary of Product Characteristics
General medicine information. Follow the instructions for your own medicine and speak to a pharmacist or clinician about your individual circumstances.